Asian Market Stocks Estimated At Up To 46.8% Discount From Intrinsic Value
As Asian markets navigate a landscape marked by fluctuating technology stocks and targeted policy support, investors are increasingly attentive to opportunities that may be undervalued. In this environment, identifying stocks trading at significant discounts from their intrinsic value can offer potential for growth, particularly when considering the broader economic conditions and market sentiment.
Top 10 Undervalued Stocks Based On Cash Flows In Asia
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Visional (TSE:4194) | ¥8878.00 | ¥17749.44 | 50% |
| Rakuten Bank (TSE:5838) | ¥5520.00 | ¥10832.18 | 49% |
| Ningbo Sanxing Medical ElectricLtd (SHSE:601567) | CN¥16.12 | CN¥31.43 | 48.7% |
| NEXTIN (KOSDAQ:A348210) | ₩31850.00 | ₩62326.56 | 48.9% |
| Matrix Design (SZSE:301365) | CN¥38.53 | CN¥75.19 | 48.8% |
| Loncin Motor (SHSE:603766) | CN¥14.01 | CN¥27.47 | 49% |
| Livero (TSE:9245) | ¥2135.00 | ¥4232.22 | 49.6% |
| ISU Petasys (KOSE:A007660) | ₩83100.00 | ₩161536.58 | 48.6% |
| Hanwha Engine (KOSE:A082740) | ₩43450.00 | ₩86878.80 | 50% |
| gremsInc (TSE:3150) | ¥2462.00 | ¥4912.25 | 49.9% |
Let's explore several standout options from the results in the screener.
Innovent Biologics (SEHK:1801)
Overview: Innovent Biologics, Inc. is a biopharmaceutical company focused on the research and development of antibody and protein medicine products across China, the United States, Europe, and other international markets, with a market cap of approximately HK$158.34 billion.
Operations: The company's revenue segment primarily consists of its biotechnology operations, generating approximately CN¥13.04 billion.
Estimated Discount To Fair Value: 45.3%
Innovent Biologics is trading at 45.3% below its estimated fair value and significantly undervalued based on discounted cash flow analysis, with a stock price of HK$90.95 against a future cash flow value estimate of HK$166.27. The company reported robust product revenue growth, over RMB 8.2 billion for the first half of 2026, driven by strong commercial performance and strategic collaborations, reinforcing its dual-engine growth strategy in biomedicine and oncology sectors.
- The analysis detailed in our Innovent Biologics growth report hints at robust future financial performance.
- Click here and access our complete balance sheet health report to understand the dynamics of Innovent Biologics.
Zhejiang Crystal-Optech (SZSE:002273)
Overview: Zhejiang Crystal-Optech Co., Ltd focuses on the research, development, and sale of optical and optoelectronics products in China with a market cap of approximately CN¥37.98 billion.
Operations: The company generates revenue from its optical and optoelectronics product segments in China.
Estimated Discount To Fair Value: 23.2%
Zhejiang Crystal-Optech is trading at CN¥27.32, below its estimated future cash flow value of CN¥35.57, indicating it is significantly undervalued by over 20%. Despite high volatility in recent months and a low forecasted return on equity of 18.2% in three years, earnings are expected to grow significantly at 23.47% per year, outpacing the market's revenue growth rate. Analysts anticipate a price rise of 31.6%, though dividends remain unstable.
- Our growth report here indicates Zhejiang Crystal-Optech may be poised for an improving outlook.
- Delve into the full analysis health report here for a deeper understanding of Zhejiang Crystal-Optech.
Auras Technology (TPEX:3324)
Overview: Auras Technology Co., Ltd. manufactures, processes, and retails electronic materials and computer cooling modules across various international markets, with a market cap of NT$98.66 billion.
Operations: The company's revenue segment for Electronic Components & Parts is NT$27.41 billion.
Estimated Discount To Fair Value: 46.8%
Auras Technology, trading at NT$1060, is significantly undervalued by 46.8% compared to its estimated future cash flow value of NT$1993.77. Recent earnings reports show strong performance with sales reaching NT$8.55 billion and net income rising to NT$1.16 billion year-over-year. Earnings are projected to grow substantially at 33.26% annually, surpassing the Taiwan market average, while analysts agree on a potential stock price increase of 32.7%.
- Upon reviewing our latest growth report, Auras Technology's projected financial performance appears quite optimistic.
- Navigate through the intricacies of Auras Technology with our comprehensive financial health report here.
Key Takeaways
- Click through to start exploring the rest of the 215 Undervalued Asian Stocks Based On Cash Flows now.
- Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
- Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.
Looking For Alternative Opportunities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com